Uncovering how ‘dark matter’ regions of the genome affect inflammatory diseases

Post author:Rose Duesterwald
Post published:May 20, 2020
Post category:Rare Disease

Promising new drug target for autoimmune and allergic diseases revealed Credit: The Babraham Institute
A study led by researchers at the Babraham Institute in collaboration with the Wellcome Sanger Institute has uncovered how variations in a non-protein coding ‘dark matter’ region of the genome could make patients susceptible to complex autoimmune and allergic diseases such as inflammatory bowel disease.

Read the source article at Scienmag

Rose Duesterwald

Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.